Particle Sciences Develops Novel Ocular Formulation For Eyeon Therapeutics
BETHLEHEM, Pa., Nov. 7, 2012 /PRNewswire/ -- Particle Sciences, a leading drug delivery CRO, has developed a novel ocular formulation for its client, Eyeon Therapeutics, Inc. The formulation, based on a polymer owned by Particle Sciences, provided superior clinical results in treating dry eye when compared to Systane®, the leading OTC dry eye product from Alcon. The results were published earlier this year in the Journal of Ocular Pharmacology and Therapeutics.
Mark Mitchnick, CEO of Particle Sciences notes that "Particle Sciences has seen an increase in the number of client's coming to us for ocular formulations. In this case, our staff came up with a new approach and worked with our client to take the idea from concept into clinical trials in a very short time."
Particle Sciences is an integrated provider of drug formulation and development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com , email firstname.lastname@example.org or contact us at (610) 861- 4701 for information.
Contact: Maureen Mattera email@example.com 1-610-861-4701SOURCE Particle Sciences
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV